290 related articles for article (PubMed ID: 25487083)
1. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group.
Marcellusi A; Capone A; Favato G; Mennini FS; Baio G; Haeussler K; Bononi M;
Clin Ther; 2015 Jan; 37(1):156-167.e4. PubMed ID: 25487083
[TBL] [Abstract][Full Text] [Related]
2. Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy.
Mennini FS; Panatto D; Marcellusi A; Cristoforoni P; De Vincenzo R; Di Capua E; Ferrandina G; Petrillo M; Sasso T; Ricci C; Trivellizzi N; Capone A; Scambia G; Gasparini R
Clin Ther; 2011 Aug; 33(8):1084-1095.e4. PubMed ID: 21788076
[TBL] [Abstract][Full Text] [Related]
3. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia.
Ezat WP; Aljunid S
Asian Pac J Cancer Prev; 2010; 11(1):79-90. PubMed ID: 20593935
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
7. Impact of HPV vaccination: health gains in the Italian female population.
Marcellusi A
Popul Health Metr; 2017 Sep; 15(1):36. PubMed ID: 28962572
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
10. Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?
Isaranuwatchai W; Graham DM; Siu LL; Hoch JS
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):763-5. PubMed ID: 25095728
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
[TBL] [Abstract][Full Text] [Related]
12. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
[TBL] [Abstract][Full Text] [Related]
15. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
16. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
18. The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia.
Sehnal B; Dusek L; Cibula D; Zima T; Halaska M; Driak D; Slama J
J Clin Virol; 2014 Jan; 59(1):18-23. PubMed ID: 24315797
[TBL] [Abstract][Full Text] [Related]
19. A multi-type HPV transmission model.
Elbasha EH; Dasbach EJ; Insinga RP
Bull Math Biol; 2008 Nov; 70(8):2126-76. PubMed ID: 18841421
[TBL] [Abstract][Full Text] [Related]
20. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
